Trial reportDiabetes care2015
Novel metabolic markers for the risk of diabetes development in American Indians.
Trial report in Diabetes care, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies.Diabetes care · 2022Pooled it
- Associations of network-derived metabolite clusters with prevalent type 2 diabetes among adults of Puerto Rican descent.BMJ open diabetes research & care · 2021Pooled it
- Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis.Diabetes care · 2016Pooled it
- Probiotic Soy Milk Consumption and Renal Function Among Type 2 Diabetic Patients with Nephropathy: a Randomized Controlled Clinical Trial.Probiotics and antimicrobial proteins · 2019Trial
- Environmental Insults to Glucose Metabolism: The Role of Pollutants in Insulin Resistance.International journal of molecular sciences · 2025Review
- Article
- Non-linear relationship between arteriosclerosis index and diabetes risk in non-obese east Asian adults.Scientific reports · 2025Article
- Understanding Patterns of the Gut Microbiome May Contribute to the Early Detection and Prevention of Type 2 Diabetes Mellitus: A Systematic Review.Microorganisms · 2025Review
- The impact of choline supplementation on oxidative stress and clinical outcomes among patients with non-alcoholic fatty liver disease: a randomized controlled study.Therapeutic advances in chronic disease · 2025Article
- Novel type 2 diabetes prediction score based on traditional risk factors and circulating metabolites: model derivation and validation in two large cohort studies.EClinicalMedicine · 2025Article
- Metabolomics insights into Charcot-Marie-Tooth disease: toward biomarker discovery.Frontiers in neurology · 2025Article
- Exploring the design of clinical research studies on the efficacy mechanisms in type 2 diabetes mellitus.Frontiers in endocrinology · 2024Review
- Integrated biomarker profiling of the metabolome associated with type 2 diabetes mellitus among Tibetan in China.Diabetology & metabolic syndrome · 2023Article
- Mitigation of Insulin Resistance by Natural Products from a New Class of Molecules, Membrane-Active Immunomodulators.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Metabolite profiles of diabetes mellitus and response to intervention in anti-hyperglycemic drugs.Frontiers in endocrinology · 2023Review
- Lipidomic profiling in the Strong Heart Study identified American Indians at risk of chronic kidney disease.Kidney international · 2022Article
- The role of NMR-based circulating metabolic biomarkers in development and risk prediction of new onset type 2 diabetes.Scientific reports · 2022Article
- Ethnic disparities attributed to the manifestation in and response to type 2 diabetes: insights from metabolomics.Metabolomics : Official journal of the Metabolomic Society · 2022Review
- Predictive value of circulating NMR metabolic biomarkers for type 2 diabetes risk in the UK Biobank study.BMC medicine · 2022Article
- Candidate metabolite markers of peripheral neuropathy in Chinese patients with type 2 diabetes.American journal of translational research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
objectiveTo identify novel metabolic markers for diabetes development in American Indians. RESEARCH DESIGN AND
methodsUsing an untargeted high-resolution liquid chromatography-mass spectrometry, we conducted metabolomics analysis of study participants who developed incident diabetes (n = 133) and those who did not (n = 298) from 2,117 normoglycemic American Indians followed for an average of 5.5 years in the Strong Heart Family Study. Relative abundances of metabolites were quantified in baseline fasting plasma of all 431 participants. Prospective association of each metabolite with risk of developing type 2 diabetes (T2D) was examined using logistic regression adjusting for established diabetes risk factors.
resultsSeven metabolites (five known and two unknown) significantly predict the risk of T2D. Notably, one metabolite matching 2-hydroxybiphenyl was significantly associated with an increased risk of diabetes, whereas four metabolites matching PC (22:6/20:4), (3S)-7-hydroxy-2',3',4',5',8-pentamethoxyisoflavan, or tetrapeptides were significantly associated with decreased risk of diabetes. A multimarker score comprising all seven metabolites significantly improved risk prediction beyond established diabetes risk factors including BMI, fasting glucose, and insulin resistance.
conclusionsThe findings suggest that these newly detected metabolites may represent novel prognostic markers of T2D in American Indians, a group suffering from a disproportionately high rate of T2D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.